ART secures two orders for molecular
MONTREAL – ART Advanced Research
Technologies Inc., a developer of optical molecular imaging products
for the healthcare and pharmaceutical industries, announced that it has
received two orders for the recently released preclinical optical
molecular imager, Optix MX2. The units are expected to be shipped before
the end of the year.
This represents the first Optix units sold by ART under its new
commercial strategy. The company said it preferred not to disclose the
names of the buyers of the new equipment.
“These orders of the Optix MX2 system demonstrate that we are on track
to achieve revenue growth with our new commercialization strategy under
the leadership of Dino DiCamillo, our new global sales and marketing
executive for preclinical imaging,” said Sebastien Gignac, President and
CEO of ART.
“ART is building sales momentum with the new team in place and
leveraging internal expertise in optical imaging to offer multiple
solutions to Optix users,” concluded Dino DiCamillo, ART’s Vice
President, Global Sales & Marketing for Preclinical Imaging.
About the Optix system
Based on time-domain technology, which allows measurement of the light’s
time of arrival, the Optix in vivo optical molecular imaging device is
the most sensitive optical imager commercially available on the
precinical market, allowing for detection of lower concentrations of
signals deeper inside the body, the company says.
Unique to the Optix system is the ability to recover fluorescence
lifetime, which can be used to separate and quantify probe distributions
depending on their respective biochemical environment. Also part of the
Optix product offering is a new CT fusion software package allowing
researchers to export the scan obtained using Optix in DICOM format, and
fuse it with Micro CT for a full 3D anatomical reference.
ART Advanced Research Technologies Inc. is a leader in molecular imaging
products for the healthcare and pharmaceutical industries. ART has
developed products in medical imaging, medical diagnostics, disease
research, and drug discovery with the goal of bringing new and better
treatments to patients faster. The Optix optical molecular imaging
system, designed for monitoring physiological changes in living systems
at the preclinical study phases of new drugs, is distributed directly by
ART in North America and Europe and is used by industry and academic
The SoftScan optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing the
SoftScan optical medical imaging device via a global strategic alliance
with GE Healthcare, a world leader in mammography and imaging.
Finally, the Fenestra line of molecular imaging contrast products
provide image enhancement for a wide range of preclinical Micro CT
applications allowing scientists to see greater detail in their imaging
studies, with potential extension into other major imaging modalities.
The distribution of the Fenestra line of imaging contrast agents is made
through GE Healthcare Bio-Science KK in Japan and is sold directly by
the Company in the rest of the world. ART’s shares are listed on the TSX
under the ticker symbol ARA. For more information on ART, visit